Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-M07D1 in recurrent or metastatic gynecologic malignancies
CTR20233640Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M07D1 in gynecological cancer, sponsored by Biokin Pharmaceutical. Started Mar 2024; status: active.
02
Drugs
BL-M07D1
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on CTR20233640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233640.